Combination Versus Sequential Therapy in Metastatic Breast Cancer

Combination versus Sequential Therapy in Metastatic Breast Cancer David Miles, Gunter von Minckwitz, Andrew D. Seidman Oncologist 2002; 7(Suppl 6): 13-19 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in breast cancer and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Describe the current and evolving role of combination therapy in the management of the breast cancer patient with advanced (metastatic) disease. Appreciate the principles of combination treatment design for breast cancer management. Describe those combination treatment regimens that are designed rationally. Explain the current status of combination or sequential treatment in the management of advanced breast cancer and how clinicians might selection options based on patient characteristics. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Nov. 27, 2002 Most Recent Review: June 10, 2005* Most Recent Update: Nov. 27, 2003 Date Credit Expires: June 10, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.

Click Here to return to the complete course listing of Incorporating Oral Capecitabine into the Treatment of Breast Cancer.